Phibro Animal Health (NASDAQ:PAHC) CEO Jack Bendheim Sells 7,040 Shares

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 7,040 shares of Phibro Animal Health stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $53.73, for a total value of $378,259.20. Following the completion of the transaction, the chief executive officer owned 1,480 shares of the company’s stock, valued at $79,520.40. The trade was a 82.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Jack Bendheim also recently made the following trade(s):

• On Tuesday, February 24th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.37, for a total transaction of $361,644.80.
• On Friday, February 20th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.42, for a total transaction of $361,996.80.
• On Wednesday, February 18th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.40, for a total transaction of $361,856.00.
• On Friday, February 13th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.96, for a total transaction of $365,798.40.
• On Wednesday, February 11th, Jack Bendheim sold 14,184 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.62, for a total transaction of $732,178.08.
• On Tuesday, February 10th, Jack Bendheim sold 58,014 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.81, for a total transaction of $3,005,705.34.
• On Thursday, February 5th, Jack Bendheim sold 110,842 shares of Phibro Animal Health stock. The stock was sold at an average price of $48.38, for a total transaction of $5,362,535.96.
• On Wednesday, February 4th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $41.15, for a total value of $144,848.00.
• On Tuesday, February 3rd, Jack Bendheim sold 9,660 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.47, for a total value of $400,600.20.
• On Friday, January 30th, Jack Bendheim sold 6,693 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.09, for a total value of $268,322.37.

Phibro Animal Health Trading Up 3.0%

PAHC opened at $54.70 on Friday. The business’s 50-day simple moving average is $43.41 and its 200-day simple moving average is $40.66. The company has a market cap of $2.22 billion, a P/E ratio of 24.31, a PEG ratio of 0.82 and a beta of 0.80. Phibro Animal Health Corporation has a one year low of $16.16 and a one year high of $56.30. The company has a debt-to-equity ratio of 2.14, a quick ratio of 1.22 and a current ratio of 3.05.

Phibro Animal Health (NASDAQ:PAHC) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.69 by $0.18. The firm had revenue of $373.91 million during the quarter, compared to the consensus estimate of $355.64 million. Phibro Animal Health had a return on equity of 38.28% and a net margin of 6.29%.Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. As a group, equities research analysts expect that Phibro Animal Health Corporation will post 1.95 EPS for the current fiscal year.

Phibro Animal Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Wednesday, March 4th will be issued a dividend of $0.12 per share. The ex-dividend date of this dividend is Wednesday, March 4th. This represents a $0.48 annualized dividend and a dividend yield of 0.9%. Phibro Animal Health’s dividend payout ratio (DPR) is currently 21.33%.

Institutional Investors Weigh In On Phibro Animal Health

Large investors have recently added to or reduced their stakes in the business. Caitlin John LLC purchased a new position in Phibro Animal Health during the 4th quarter valued at about $266,000. Mackenzie Financial Corp grew its position in shares of Phibro Animal Health by 7.1% in the fourth quarter. Mackenzie Financial Corp now owns 50,619 shares of the company’s stock valued at $1,895,000 after purchasing an additional 3,355 shares during the last quarter. XTX Topco Ltd increased its stake in shares of Phibro Animal Health by 125.4% during the 4th quarter. XTX Topco Ltd now owns 16,233 shares of the company’s stock worth $606,000 after purchasing an additional 9,032 shares in the last quarter. Zacks Investment Management increased its stake in shares of Phibro Animal Health by 13.2% during the 4th quarter. Zacks Investment Management now owns 91,391 shares of the company’s stock worth $3,414,000 after purchasing an additional 10,642 shares in the last quarter. Finally, VARCOV Co. acquired a new position in shares of Phibro Animal Health during the 4th quarter worth approximately $672,000. 99.34% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on PAHC shares. Weiss Ratings restated a “buy (b-)” rating on shares of Phibro Animal Health in a research report on Monday, December 29th. JPMorgan Chase & Co. increased their price target on shares of Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Morgan Stanley set a $49.00 price objective on shares of Phibro Animal Health in a research note on Friday, February 6th. Finally, Zacks Research lowered shares of Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Monday, February 9th. Two research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Phibro Animal Health currently has a consensus rating of “Hold” and a consensus price target of $37.50.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.